Amphastar Pharmaceuticals（29A）株式概要バイオ医薬品会社であるアンファスター・ファーマシューティカルズ・インクは、米国、中国、フランスにおいて、ジェネリック医薬品および独自の注射剤、吸入剤、経鼻剤の開発、製造、販売、マーケティングを行っている。 詳細29A ファンダメンタル分析スノーフレーク・スコア評価6/6将来の成長0/6過去の実績2/6財務の健全性3/6配当金0/6報酬当社が推定した公正価値より76.6%で取引されている 同業他社や業界と比較して、良好な取引価格 アナリストらは、株価が26.7%上昇するだろうとほぼ一致している。 リスク分析今後3年間の収益は年平均0.7%減少すると予測されている。 多額の負債を抱えている German市場と比較した過去 3 か月間の株価の変動利益率(11%)は昨年より低い(19.4%) すべてのリスクチェックを見る29A Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€15.4418.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-4m867m2016201920222025202620282031Revenue US$866.5mEarnings US$95.3mAdvancedSet Fair ValueView all narrativesAmphastar Pharmaceuticals, Inc. 競合他社Dermapharm HoldingSymbol: XTRA:DMPMarket cap: €2.4bMerck KGaASymbol: XTRA:MRKMarket cap: €56.5bGerresheimerSymbol: XTRA:GXIMarket cap: €932.6mSCHOTT Pharma KGaASymbol: XTRA:1SXPMarket cap: €2.6b価格と性能株価の高値、安値、推移の概要Amphastar Pharmaceuticals過去の株価現在の株価US$15.4452週高値US$25.9652週安値US$13.90ベータ0.971ヶ月の変化-11.62%3ヶ月変化-32.66%1年変化-26.89%3年間の変化-61.97%5年間の変化0.26%IPOからの変化47.02%最新ニュースBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. CFO, Executive VP of Finance, Treasurer & Director Bill Peters was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 30Amphastar Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 07, 2026Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026お知らせ • Apr 14Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2026Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2026.お知らせ • Feb 20Amphastar Pharmaceuticals, Inc. to Report Q4, 2025 Results on Feb 26, 2026Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 26, 2026お知らせ • Oct 27Amphastar Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025お知らせ • Jul 29Amphastar Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025最新情報をもっと見るRecent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. CFO, Executive VP of Finance, Treasurer & Director Bill Peters was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 30Amphastar Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 07, 2026Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026お知らせ • Apr 14Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2026Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2026.お知らせ • Feb 20Amphastar Pharmaceuticals, Inc. to Report Q4, 2025 Results on Feb 26, 2026Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 26, 2026お知らせ • Oct 27Amphastar Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025お知らせ • Jul 29Amphastar Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025お知らせ • Jul 22Amphastar Pharmaceuticals, Inc. Appoints David Gaugh to Serve as A Class I DirectorOn July 18, 2025, the Board of Directors (the “Board”) of Amphastar Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), approved an increase to the authorized number of directors permitted to serve on the Board from ten (10) to eleven (11) directors and appointed David Gaugh, to serve as a Class I director, to hold office until the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal, effective immediately. Mr. Gaugh was not appointed to serve on any committees of the Board at this time.お知らせ • Jun 30Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic IndexAmphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Indexお知らせ • Apr 30Amphastar Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 07, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025お知らせ • Apr 05Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2025Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2025.お知らせ • Feb 21Amphastar Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 27, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2024 results After-Market on Feb 27, 2025New Risk • Nov 15New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €241k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (48% net debt to equity). Significant insider selling over the past 3 months (€241k sold).Reported Earnings • Nov 08Third quarter 2024 earnings released: EPS: US$0.83 (vs US$1.01 in 3Q 2023)Third quarter 2024 results: EPS: US$0.83 (down from US$1.01 in 3Q 2023). Revenue: US$191.2m (up 5.9% from 3Q 2023). Net income: US$40.4m (down 18% from 3Q 2023). Profit margin: 21% (down from 27% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year whereas the company’s share price has increased by 35% per year.お知らせ • Oct 29Amphastar Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024New Risk • Sep 09New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €241k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (52% net debt to equity). Significant insider selling over the past 3 months (€241k sold).Reported Earnings • Aug 08Second quarter 2024 earnings released: EPS: US$0.78 (vs US$0.54 in 2Q 2023)Second quarter 2024 results: EPS: US$0.78 (up from US$0.54 in 2Q 2023). Revenue: US$182.4m (up 25% from 2Q 2023). Net income: US$37.9m (up 45% from 2Q 2023). Profit margin: 21% (up from 18% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 01Amphastar Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024お知らせ • Jun 06Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as DirectorAmphastar Pharmaceuticals, Inc. at its Annual General Meeting held on June 3, 2024, approved the appointment of Howard Lee as director to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.お知らせ • May 23Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation AerosolAmphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with irreversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients 4 years of age and older. The FDA determined that Amphastar's albuterol is bioequivalent and therapeutically equivalent to Teva Respiratory LLC's ProAir®? HFA(albuterol sulfate) Inhalation Aerosol. Amphastar plans to launch its Albuterol Sulfate Inhalation Aerosol in the third quarter of 2024.Reported Earnings • May 09First quarter 2024 earnings released: EPS: US$0.90 (vs US$0.54 in 1Q 2023)First quarter 2024 results: EPS: US$0.90 (up from US$0.54 in 1Q 2023). Revenue: US$171.8m (up 23% from 1Q 2023). Net income: US$43.2m (up 66% from 1Q 2023). Profit margin: 25% (up from 19% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.お知らせ • May 01Amphastar Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024お知らせ • Apr 13Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024, at 11:00 Pacific Standard Time. Agenda: To elect four Class II directors to hold office for a three-year term and until their respective successors are duly elected and qualified or until such director’s earlier death, resignation or removal; to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for our fiscal year ending December 31, 2024; to approve, on an advisory basis, the compensation of named executive officers; to approve the amendment and restatement of the Company’s 2015 Equity Incentive Plan; and to transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.Recent Insider Transactions • Mar 08Insider recently sold €543k worth of stockOn the 5th of March, Michael Zasloff sold around 13k shares on-market at roughly €43.41 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.9m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €43.20, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 175% over the past three years.Reported Earnings • Mar 01Full year 2023 earnings released: EPS: US$2.85 (vs US$1.88 in FY 2022)Full year 2023 results: EPS: US$2.85 (up from US$1.88 in FY 2022). Revenue: US$644.4m (up 29% from FY 2022). Net income: US$137.5m (up 51% from FY 2022). Profit margin: 21% (up from 18% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 29Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023Amphastar Pharmaceuticals, Inc. reported impairment of long-lived assets for the fourth quarter ended December 31, 2023. For the quarter, the company reported impairment of long-lived assets of $1,000.お知らせ • Feb 21Amphastar Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2023 results After-Market on Feb 28, 2024Valuation Update With 7 Day Price Move • Jan 12Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €48.40, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 208% over the past three years.Recent Insider Transactions • Nov 17Lead Independent Director recently sold €245k worth of stockOn the 13th of November, Richard Prins sold around 5k shares on-market at roughly €49.08 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.2m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Nov 15Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €52.50, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 228% over the past three years.Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: US$1.01 (vs US$0.33 in 3Q 2022)Third quarter 2023 results: EPS: US$1.01 (up from US$0.33 in 3Q 2022). Revenue: US$180.6m (up 50% from 3Q 2022). Net income: US$49.2m (up 210% from 3Q 2022). Profit margin: 27% (up from 13% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 02Amphastar Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023Recent Insider Transactions • Aug 18Insider recently sold €668k worth of stockOn the 15th of August, Michael Zasloff sold around 13k shares on-market at roughly €52.37 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.6m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Aug 16Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €48.60, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 21x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 188% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €73.37 per share.New Risk • Aug 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Minor Risk Significant insider selling over the past 3 months (€734k sold).Reported Earnings • Aug 09Second quarter 2023 earnings released: EPS: US$0.54 (vs US$0.35 in 2Q 2022)Second quarter 2023 results: EPS: US$0.54 (up from US$0.35 in 2Q 2022). Revenue: US$145.7m (up 18% from 2Q 2022). Net income: US$26.1m (up 51% from 2Q 2022). Profit margin: 18% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 03Amphastar Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €57.00, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 228% over the past three years.New Risk • Jul 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Significant insider selling over the past 3 months (€734k sold).Valuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €49.40, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 170% over the past three years.Recent Insider Transactions • May 18Insider recently sold €291k worth of stockOn the 15th of May, Michael Zasloff sold around 8k shares on-market at roughly €38.80 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €3.8m more than they bought in the last 12 months.Reported Earnings • May 10First quarter 2023 earnings released: EPS: US$0.54 (vs US$0.50 in 1Q 2022)First quarter 2023 results: EPS: US$0.54 (up from US$0.50 in 1Q 2022). Revenue: US$140.0m (up 16% from 1Q 2022). Net income: US$26.0m (up 7.3% from 1Q 2022). Profit margin: 19% (down from 20% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.お知らせ • May 04Amphastar Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 09, 2023Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 09, 2023Valuation Update With 7 Day Price Move • Apr 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €32.00, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 100% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.56 per share.Reported Earnings • Mar 02Full year 2022 earnings released: EPS: US$1.88 (vs US$1.30 in FY 2021)Full year 2022 results: EPS: US$1.88 (up from US$1.30 in FY 2021). Revenue: US$499.0m (up 14% from FY 2021). Net income: US$91.4m (up 47% from FY 2021). Profit margin: 18% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 09Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.61 in 3Q 2021)Third quarter 2022 results: EPS: US$0.33 (down from US$0.61 in 3Q 2021). Revenue: US$120.1m (up 7.1% from 3Q 2021). Net income: US$15.9m (down 46% from 3Q 2021). Profit margin: 13% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 29Amphastar Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022Valuation Update With 7 Day Price Move • Aug 16Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €30.40, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 53% over the past three years.Reported Earnings • Aug 10Second quarter 2022 earnings released: EPS: US$0.35 (vs US$0.16 in 2Q 2021)Second quarter 2022 results: EPS: US$0.35 (up from US$0.16 in 2Q 2021). Revenue: US$123.5m (up 21% from 2Q 2021). Net income: US$17.3m (up 123% from 2Q 2021). Profit margin: 14% (up from 7.6% in 2Q 2021). Over the next year, revenue is forecast to grow 10%, compared to a 6.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 25% per year.お知らせ • Aug 10Amphastar Pharmaceuticals, Inc. Announces Executive ChangesOn August 4, 2022, the Board of Directors of Amphastar Pharmaceuticals, Inc. upon the recommendation of the Nominating and Corporate Governance Committee of the Board approved an increase to the authorized number of directors permitted to serve on the Board from eight (8) to ten (10) directors and appointed each of William J. Peters, the Company’s Chief Financial Officer, Executive Vice President of Finance, and Treasurer, and Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, and Sales and Marketing (together with Mr. Peters, the “New Directors”), to serve as Class I directors, to hold office until the Company’s 2023 annual meeting of stockholders and until each such director’s successor is duly elected and qualified or until each such director’s earlier death, resignation or removal, effective immediately. The Board also determined that Diane G. Gerst does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director that, including Ms. Gerst, six of the Company’s current directors are independent of within the meaning of the listing standards of the Nasdaq Stock Market LLC.お知らせ • Aug 02Amphastar Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2022 results After-Market on Aug 08, 2022Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to €38.80, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 13x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 129% over the past three years.Recent Insider Transactions • May 22Chairman of the Board recently sold €3.5m worth of stockOn the 19th of May, Ziping Luo sold around 109k shares on-market at roughly €32.11 per share. This was the largest sale by an insider in the last 3 months. This was Ziping's only on-market trade for the last 12 months.Reported Earnings • May 11First quarter 2022 earnings released: EPS: US$0.50 (vs US$0.11 in 1Q 2021)First quarter 2022 results: EPS: US$0.50 (up from US$0.11 in 1Q 2021). Revenue: US$120.4m (up 17% from 1Q 2021). Net income: US$24.3m (up 381% from 1Q 2021). Profit margin: 20% (up from 4.9% in 1Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 15%, compared to a 6.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 17% per year.お知らせ • May 04Amphastar Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2022 results After-Market on May 09, 2022お知らせ • Apr 15Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022, at 11:00 Pacific Standard Time. Agenda: To consider and elect three class III directors to hold office for a three-year term and until their respective successors are duly elected and qualified or until such director’s earlier death, resignation or removal; to consider and ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2022; to consider and approve on an advisory basis, the compensation of our named executive officers; and to transact such other business as may properly come before the annual meeting and any adjournments or postponements thereof.Reported Earnings • Mar 12Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: US$1.30 (up from US$0.03 in FY 2020). Revenue: US$437.8m (up 25% from FY 2020). Net income: US$62.1m (up US$60.7m from FY 2020). Profit margin: 14% (up from 0.4% in FY 2020). The increase in margin was driven by higher revenue. Post-clinical trial products Pre-registration: 5 Launched (during full year): 1 Revenue exceeded analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 11%, compared to a 8.1% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 09Third quarter 2021 earnings released: EPS US$0.61 (vs US$0.083 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$112.2m (up 35% from 3Q 2020). Net income: US$29.5m (up US$25.6m from 3Q 2020). Profit margin: 26% (up from 4.7% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Executive Departure • Aug 24Independent Director David Maris has left the companyOn the 19th of August, David Maris' tenure as Independent Director ended after 1.2 years in the role. As of June 2021, David still personally held 7.30k shares (€123k worth at the time). David is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 13.96 years.お知らせ • Aug 21Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH) entered into a share purchase agreement to acquire the remaining 15% stake in Amphastar Nanjing Pharmaceuticals, Co., Ltd., from Applied Physics & Chemistry Laboratories, Inc., Bill Zhang and Chongqing Zhang for $22.5 million.Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH) entered into a share purchase agreement to acquire the remaining 15% stake in Amphastar Nanjing Pharmaceuticals, Co., Ltd., from Applied Physics & Chemistry Laboratories, Inc., Bill Zhang and Chongqing Zhang for $22.5 million on August 19, 2021. Pursuant to the terms of the transaction, Amphastar Pharmaceuticals, Inc., shall pay $18.9 million to Applied Physics & Chemistry Laboratories, Inc., $3.4 million to Bill Zhang and $0.21 million to Chongqing Zhang. Following completion of the transaction, Amphastar Pharmaceuticals, Inc., will own 100% of Amphastar Nanjing Pharmaceuticals, Co., Ltd.Reported Earnings • Aug 10Second quarter 2021 earnings released: EPS US$0.16 (vs US$0.004 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$101.7m (up 19% from 2Q 2020). Net income: US$7.77m (up US$7.96m from 2Q 2020). Profit margin: 7.6% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.Recent Insider Transactions • Jun 13Insider recently sold €76k worth of stockOn the 9th of June, Rong Zhou sold around 5k shares on-market at roughly €16.07 per share. In the last 3 months, they made an even bigger sale worth €102k. Insiders have been net sellers, collectively disposing of €462k more than they bought in the last 12 months.Recent Insider Transactions • May 15Insider recently sold €73k worth of stockOn the 12th of May, Jacob Liawatidewi sold around 5k shares on-market at roughly €16.00 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €414k more than they bought in the last 12 months.Reported Earnings • May 08First quarter 2021 earnings released: EPS US$0.11 (vs US$0.085 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$103.0m (up 22% from 1Q 2020). Net income: US$5.04m (up 28% from 1Q 2020). Profit margin: 4.9% (up from 4.7% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • May 04Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Morphine Sulfate InjectionAmphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration approved the Company’s Abbreviated New Drug Application for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet® Prefilled Syringe System. It is indicated for the management of pain severe enough to require use of an opioid analgesic by Patient-Controlled Analgesia (PCA), only for use with a compatible Alaris® infusion device, and for which alternative treatments are inadequate. For the past 30 years, the company has sold and marketed the product under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program.Reported Earnings • Mar 17Full year 2020 earnings released: EPS US$0.03 (vs US$1.04 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: US$349.8m (up 8.5% from FY 2019). Net income: US$1.40m (down 97% from FY 2019). Profit margin: 0.4% (down from 15% in FY 2019). Post-clinical trial products Pre-registration: 6 Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 10Amphastar Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 15, 2021Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2020 results After-Market on Mar 15, 2021Is New 90 Day High Low • Feb 25New 90-day low: €14.50The company is down 2.0% from its price of €14.80 on 26 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €66.42 per share.お知らせ • Jan 28Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic IndexAmphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Indexお知らせ • Dec 30Amphastar Announces Approval for Glucagon for Injection Kit, 1mgAmphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin. Amphastar plans to launch this Glucagon for Injection Emergency Kit, which it previously referred to as AMP-001, within two months. The Company currently has four ANDAs filed with the FDA, which are targeting products with a market size of approximately $1.4 billion, three biosimilar products in development targeting products with a market size of approximately $13.0 billion, and nine generic products in development targeting products with a market size of approximately $12.0 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2020. The Company is developing multiple proprietary pipeline products for injectable and intranasal dosage forms, including a new drug application for intranasal naloxone and intranasal epinephrine. Amphastar’s Chinese subsidiary, ANP, currently has 14 Drug Master Files, or DMF, on file with the FDA and is developing several additional DMFs.Is New 90 Day High Low • Nov 24New 90-day low: €15.00The company is down 12% from its price of €17.00 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €57.82 per share.Analyst Estimate Surprise Post Earnings • Nov 07Revenue misses expectationsRevenue missed analyst estimates by 8.6%. Over the next year, revenue is forecast to grow 29%, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany.Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS US$0.083The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$83.4m (up 4.1% from 3Q 2019). Net income: US$3.92m (up 199% from 3Q 2019). Profit margin: 4.7% (up from 1.6% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 30Amphastar Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 06, 2020Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Nov 06, 2020お知らせ • Oct 07Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate InjectionAmphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration approved the Company’s Abbreviated New Drug Application for Atropine Sulfate injection 0.1mg/mL in the 10 mL Luer-Jet® Prefilled Syringe System. For the past 40 years, the Company has sold and marketed the product under the “grandfather” exception (now termed unapproved) to the FDA’s “Prescription Drug Wrap-Up” program. Net revenues for the Company’s Atropine Sulfate injection for the year ended December 31, 2019 were $12.2 million.Is New 90 Day High Low • Sep 23New 90-day low: €15.80The company is down 16% from its price of €18.80 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €49.06 per share.お知らせ • Jul 31Amphastar Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 06, 2020お知らせ • Jul 04Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic IndexAmphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index株主還元29ADE PharmaceuticalsDE 市場7D11.1%6.4%3.9%1Y-26.9%26.5%2.6%株主還元を見る業界別リターン: 29A過去 1 年間で26.5 % の収益を上げたGerman Pharmaceuticals業界を下回りました。リターン対市場: 29Aは、過去 1 年間で2.6 % のリターンを上げたGerman市場を下回りました。価格変動Is 29A's price volatile compared to industry and market?29A volatility29A Average Weekly Movement10.2%Pharmaceuticals Industry Average Movement6.4%Market Average Movement6.1%10% most volatile stocks in DE Market12.9%10% least volatile stocks in DE Market2.7%安定した株価: 29Aの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 29Aの weekly volatility ( 10% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19961,976Jack Zhangwww.amphastar.comバイオ医薬品会社であるアンファスター・ファーマシューティカルズ・インクは、米国、中国、フランスにおいて、ジェネリック医薬品および独自の注射剤、吸入剤、経鼻剤の開発、製造、販売、マーケティングを行っている。重度の低血糖症治療用点鼻薬BAQSIMI、間欠性喘息の軽度の症状を一時的に緩和する市販のエピネフリン吸入製剤Primatene Mist、深部静脈血栓症の予防と治療用エノキサパリン、オピオイド過剰摂取用REXTOVYとNaloxone、注射用緊急キットGlucagon、副腎皮質機能不全患者のスクリーニング用診断薬Cortrosynを提供している。また、牛由来ヒアルロニダーゼ注射剤Amphadase、アレルギー反応用エピネフリン注射剤、泌尿器科処置用麻酔剤リドカインゼリー、各種処置用リドカイン外用液、新生児用ビタミンK1注射剤フィトナジオン注射剤、緊急用注射器製品、患者管理鎮痛ポンプ用モルヒネ注射剤、手術・医療処置用ロラゼパム注射剤も提供している。さらに、重症筋無力症の治療や筋弛緩剤の効果を逆転させるネオスチグミンメチル硫酸塩注射剤、軽度または一過性の心ブロックエピソードに用いるイソプロテレノール塩酸塩注射剤、早発黄体形成ホルモンの急上昇を抑制するガニレリクス酢酸塩注射剤、血圧を上昇させるバソプレシン、放射性核種心筋灌流イメージング用ストレス剤であるレガデノソン、吸入用エアゾールであるアルブテロール硫酸塩も提供している。さらに、同社は遺伝子組換えヒトインスリン原薬とブタインスリン原薬を販売している。さらに、注射剤、吸入剤、分析技術などのジェネリック製品候補、バイオシミラー製品候補、アレルギー反応治療用のエピネフリン経鼻剤の開発も行っている。同社は1996年に設立され、カリフォルニア州ランチョクカモンガに本社を置いている。もっと見るAmphastar Pharmaceuticals, Inc. 基礎のまとめAmphastar Pharmaceuticals の収益と売上を時価総額と比較するとどうか。29A 基礎統計学時価総額€697.29m収益（TTM）€68.06m売上高(TTM)€618.94m10.2xPER（株価収益率1.1xP/Sレシオ29A は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計29A 損益計算書（TTM）収益US$720.53m売上原価US$379.40m売上総利益US$341.13mその他の費用US$261.90m収益US$79.23m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）1.80グロス・マージン47.34%純利益率11.00%有利子負債／自己資本比率79.0%29A の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 13:28終値2026/05/25 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Amphastar Pharmaceuticals, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Glen SantangeloBarclaysGary NachmanBMO Capital Markets Equity ResearchPavan PatelBofA Global Research11 その他のアナリストを表示
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. CFO, Executive VP of Finance, Treasurer & Director Bill Peters was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 30Amphastar Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 07, 2026Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
お知らせ • Apr 14Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2026Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2026.
お知らせ • Feb 20Amphastar Pharmaceuticals, Inc. to Report Q4, 2025 Results on Feb 26, 2026Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 26, 2026
お知らせ • Oct 27Amphastar Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025
お知らせ • Jul 29Amphastar Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. CFO, Executive VP of Finance, Treasurer & Director Bill Peters was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 30Amphastar Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 07, 2026Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
お知らせ • Apr 14Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2026Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2026.
お知らせ • Feb 20Amphastar Pharmaceuticals, Inc. to Report Q4, 2025 Results on Feb 26, 2026Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 26, 2026
お知らせ • Oct 27Amphastar Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025
お知らせ • Jul 29Amphastar Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025
お知らせ • Jul 22Amphastar Pharmaceuticals, Inc. Appoints David Gaugh to Serve as A Class I DirectorOn July 18, 2025, the Board of Directors (the “Board”) of Amphastar Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), approved an increase to the authorized number of directors permitted to serve on the Board from ten (10) to eleven (11) directors and appointed David Gaugh, to serve as a Class I director, to hold office until the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal, effective immediately. Mr. Gaugh was not appointed to serve on any committees of the Board at this time.
お知らせ • Jun 30Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic IndexAmphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index
お知らせ • Apr 30Amphastar Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 07, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025
お知らせ • Apr 05Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2025Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2025.
お知らせ • Feb 21Amphastar Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 27, 2025Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2024 results After-Market on Feb 27, 2025
New Risk • Nov 15New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €241k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (48% net debt to equity). Significant insider selling over the past 3 months (€241k sold).
Reported Earnings • Nov 08Third quarter 2024 earnings released: EPS: US$0.83 (vs US$1.01 in 3Q 2023)Third quarter 2024 results: EPS: US$0.83 (down from US$1.01 in 3Q 2023). Revenue: US$191.2m (up 5.9% from 3Q 2023). Net income: US$40.4m (down 18% from 3Q 2023). Profit margin: 21% (down from 27% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year whereas the company’s share price has increased by 35% per year.
お知らせ • Oct 29Amphastar Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024
New Risk • Sep 09New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €241k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (52% net debt to equity). Significant insider selling over the past 3 months (€241k sold).
Reported Earnings • Aug 08Second quarter 2024 earnings released: EPS: US$0.78 (vs US$0.54 in 2Q 2023)Second quarter 2024 results: EPS: US$0.78 (up from US$0.54 in 2Q 2023). Revenue: US$182.4m (up 25% from 2Q 2023). Net income: US$37.9m (up 45% from 2Q 2023). Profit margin: 21% (up from 18% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 01Amphastar Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024
お知らせ • Jun 06Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as DirectorAmphastar Pharmaceuticals, Inc. at its Annual General Meeting held on June 3, 2024, approved the appointment of Howard Lee as director to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified.
お知らせ • May 23Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation AerosolAmphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with irreversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients 4 years of age and older. The FDA determined that Amphastar's albuterol is bioequivalent and therapeutically equivalent to Teva Respiratory LLC's ProAir®? HFA(albuterol sulfate) Inhalation Aerosol. Amphastar plans to launch its Albuterol Sulfate Inhalation Aerosol in the third quarter of 2024.
Reported Earnings • May 09First quarter 2024 earnings released: EPS: US$0.90 (vs US$0.54 in 1Q 2023)First quarter 2024 results: EPS: US$0.90 (up from US$0.54 in 1Q 2023). Revenue: US$171.8m (up 23% from 1Q 2023). Net income: US$43.2m (up 66% from 1Q 2023). Profit margin: 25% (up from 19% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.
お知らせ • May 01Amphastar Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024
お知らせ • Apr 13Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024, at 11:00 Pacific Standard Time. Agenda: To elect four Class II directors to hold office for a three-year term and until their respective successors are duly elected and qualified or until such director’s earlier death, resignation or removal; to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for our fiscal year ending December 31, 2024; to approve, on an advisory basis, the compensation of named executive officers; to approve the amendment and restatement of the Company’s 2015 Equity Incentive Plan; and to transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
Recent Insider Transactions • Mar 08Insider recently sold €543k worth of stockOn the 5th of March, Michael Zasloff sold around 13k shares on-market at roughly €43.41 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.9m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €43.20, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 175% over the past three years.
Reported Earnings • Mar 01Full year 2023 earnings released: EPS: US$2.85 (vs US$1.88 in FY 2022)Full year 2023 results: EPS: US$2.85 (up from US$1.88 in FY 2022). Revenue: US$644.4m (up 29% from FY 2022). Net income: US$137.5m (up 51% from FY 2022). Profit margin: 21% (up from 18% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 29Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023Amphastar Pharmaceuticals, Inc. reported impairment of long-lived assets for the fourth quarter ended December 31, 2023. For the quarter, the company reported impairment of long-lived assets of $1,000.
お知らせ • Feb 21Amphastar Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2023 results After-Market on Feb 28, 2024
Valuation Update With 7 Day Price Move • Jan 12Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €48.40, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 208% over the past three years.
Recent Insider Transactions • Nov 17Lead Independent Director recently sold €245k worth of stockOn the 13th of November, Richard Prins sold around 5k shares on-market at roughly €49.08 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.2m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Nov 15Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €52.50, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 228% over the past three years.
Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: US$1.01 (vs US$0.33 in 3Q 2022)Third quarter 2023 results: EPS: US$1.01 (up from US$0.33 in 3Q 2022). Revenue: US$180.6m (up 50% from 3Q 2022). Net income: US$49.2m (up 210% from 3Q 2022). Profit margin: 27% (up from 13% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 02Amphastar Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023
Recent Insider Transactions • Aug 18Insider recently sold €668k worth of stockOn the 15th of August, Michael Zasloff sold around 13k shares on-market at roughly €52.37 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.6m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Aug 16Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €48.60, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 21x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 188% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €73.37 per share.
New Risk • Aug 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Minor Risk Significant insider selling over the past 3 months (€734k sold).
Reported Earnings • Aug 09Second quarter 2023 earnings released: EPS: US$0.54 (vs US$0.35 in 2Q 2022)Second quarter 2023 results: EPS: US$0.54 (up from US$0.35 in 2Q 2022). Revenue: US$145.7m (up 18% from 2Q 2022). Net income: US$26.1m (up 51% from 2Q 2022). Profit margin: 18% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 03Amphastar Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023
Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €57.00, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 228% over the past three years.
New Risk • Jul 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Significant insider selling over the past 3 months (€734k sold).
Valuation Update With 7 Day Price Move • Jun 19Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €49.40, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 170% over the past three years.
Recent Insider Transactions • May 18Insider recently sold €291k worth of stockOn the 15th of May, Michael Zasloff sold around 8k shares on-market at roughly €38.80 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €3.8m more than they bought in the last 12 months.
Reported Earnings • May 10First quarter 2023 earnings released: EPS: US$0.54 (vs US$0.50 in 1Q 2022)First quarter 2023 results: EPS: US$0.54 (up from US$0.50 in 1Q 2022). Revenue: US$140.0m (up 16% from 1Q 2022). Net income: US$26.0m (up 7.3% from 1Q 2022). Profit margin: 19% (down from 20% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth.
お知らせ • May 04Amphastar Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 09, 2023Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 09, 2023
Valuation Update With 7 Day Price Move • Apr 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €32.00, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 100% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.56 per share.
Reported Earnings • Mar 02Full year 2022 earnings released: EPS: US$1.88 (vs US$1.30 in FY 2021)Full year 2022 results: EPS: US$1.88 (up from US$1.30 in FY 2021). Revenue: US$499.0m (up 14% from FY 2021). Net income: US$91.4m (up 47% from FY 2021). Profit margin: 18% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 09Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.61 in 3Q 2021)Third quarter 2022 results: EPS: US$0.33 (down from US$0.61 in 3Q 2021). Revenue: US$120.1m (up 7.1% from 3Q 2021). Net income: US$15.9m (down 46% from 3Q 2021). Profit margin: 13% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 29Amphastar Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022
Valuation Update With 7 Day Price Move • Aug 16Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €30.40, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 53% over the past three years.
Reported Earnings • Aug 10Second quarter 2022 earnings released: EPS: US$0.35 (vs US$0.16 in 2Q 2021)Second quarter 2022 results: EPS: US$0.35 (up from US$0.16 in 2Q 2021). Revenue: US$123.5m (up 21% from 2Q 2021). Net income: US$17.3m (up 123% from 2Q 2021). Profit margin: 14% (up from 7.6% in 2Q 2021). Over the next year, revenue is forecast to grow 10%, compared to a 6.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 25% per year.
お知らせ • Aug 10Amphastar Pharmaceuticals, Inc. Announces Executive ChangesOn August 4, 2022, the Board of Directors of Amphastar Pharmaceuticals, Inc. upon the recommendation of the Nominating and Corporate Governance Committee of the Board approved an increase to the authorized number of directors permitted to serve on the Board from eight (8) to ten (10) directors and appointed each of William J. Peters, the Company’s Chief Financial Officer, Executive Vice President of Finance, and Treasurer, and Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, and Sales and Marketing (together with Mr. Peters, the “New Directors”), to serve as Class I directors, to hold office until the Company’s 2023 annual meeting of stockholders and until each such director’s successor is duly elected and qualified or until each such director’s earlier death, resignation or removal, effective immediately. The Board also determined that Diane G. Gerst does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director that, including Ms. Gerst, six of the Company’s current directors are independent of within the meaning of the listing standards of the Nasdaq Stock Market LLC.
お知らせ • Aug 02Amphastar Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2022 results After-Market on Aug 08, 2022
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to €38.80, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 13x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 129% over the past three years.
Recent Insider Transactions • May 22Chairman of the Board recently sold €3.5m worth of stockOn the 19th of May, Ziping Luo sold around 109k shares on-market at roughly €32.11 per share. This was the largest sale by an insider in the last 3 months. This was Ziping's only on-market trade for the last 12 months.
Reported Earnings • May 11First quarter 2022 earnings released: EPS: US$0.50 (vs US$0.11 in 1Q 2021)First quarter 2022 results: EPS: US$0.50 (up from US$0.11 in 1Q 2021). Revenue: US$120.4m (up 17% from 1Q 2021). Net income: US$24.3m (up 381% from 1Q 2021). Profit margin: 20% (up from 4.9% in 1Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 15%, compared to a 6.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 17% per year.
お知らせ • May 04Amphastar Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2022 results After-Market on May 09, 2022
お知らせ • Apr 15Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022, at 11:00 Pacific Standard Time. Agenda: To consider and elect three class III directors to hold office for a three-year term and until their respective successors are duly elected and qualified or until such director’s earlier death, resignation or removal; to consider and ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2022; to consider and approve on an advisory basis, the compensation of our named executive officers; and to transact such other business as may properly come before the annual meeting and any adjournments or postponements thereof.
Reported Earnings • Mar 12Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: US$1.30 (up from US$0.03 in FY 2020). Revenue: US$437.8m (up 25% from FY 2020). Net income: US$62.1m (up US$60.7m from FY 2020). Profit margin: 14% (up from 0.4% in FY 2020). The increase in margin was driven by higher revenue. Post-clinical trial products Pre-registration: 5 Launched (during full year): 1 Revenue exceeded analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 11%, compared to a 8.1% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 09Third quarter 2021 earnings released: EPS US$0.61 (vs US$0.083 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$112.2m (up 35% from 3Q 2020). Net income: US$29.5m (up US$25.6m from 3Q 2020). Profit margin: 26% (up from 4.7% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Executive Departure • Aug 24Independent Director David Maris has left the companyOn the 19th of August, David Maris' tenure as Independent Director ended after 1.2 years in the role. As of June 2021, David still personally held 7.30k shares (€123k worth at the time). David is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 13.96 years.
お知らせ • Aug 21Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH) entered into a share purchase agreement to acquire the remaining 15% stake in Amphastar Nanjing Pharmaceuticals, Co., Ltd., from Applied Physics & Chemistry Laboratories, Inc., Bill Zhang and Chongqing Zhang for $22.5 million.Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH) entered into a share purchase agreement to acquire the remaining 15% stake in Amphastar Nanjing Pharmaceuticals, Co., Ltd., from Applied Physics & Chemistry Laboratories, Inc., Bill Zhang and Chongqing Zhang for $22.5 million on August 19, 2021. Pursuant to the terms of the transaction, Amphastar Pharmaceuticals, Inc., shall pay $18.9 million to Applied Physics & Chemistry Laboratories, Inc., $3.4 million to Bill Zhang and $0.21 million to Chongqing Zhang. Following completion of the transaction, Amphastar Pharmaceuticals, Inc., will own 100% of Amphastar Nanjing Pharmaceuticals, Co., Ltd.
Reported Earnings • Aug 10Second quarter 2021 earnings released: EPS US$0.16 (vs US$0.004 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$101.7m (up 19% from 2Q 2020). Net income: US$7.77m (up US$7.96m from 2Q 2020). Profit margin: 7.6% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
Recent Insider Transactions • Jun 13Insider recently sold €76k worth of stockOn the 9th of June, Rong Zhou sold around 5k shares on-market at roughly €16.07 per share. In the last 3 months, they made an even bigger sale worth €102k. Insiders have been net sellers, collectively disposing of €462k more than they bought in the last 12 months.
Recent Insider Transactions • May 15Insider recently sold €73k worth of stockOn the 12th of May, Jacob Liawatidewi sold around 5k shares on-market at roughly €16.00 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €414k more than they bought in the last 12 months.
Reported Earnings • May 08First quarter 2021 earnings released: EPS US$0.11 (vs US$0.085 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$103.0m (up 22% from 1Q 2020). Net income: US$5.04m (up 28% from 1Q 2020). Profit margin: 4.9% (up from 4.7% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • May 04Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Morphine Sulfate InjectionAmphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration approved the Company’s Abbreviated New Drug Application for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet® Prefilled Syringe System. It is indicated for the management of pain severe enough to require use of an opioid analgesic by Patient-Controlled Analgesia (PCA), only for use with a compatible Alaris® infusion device, and for which alternative treatments are inadequate. For the past 30 years, the company has sold and marketed the product under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program.
Reported Earnings • Mar 17Full year 2020 earnings released: EPS US$0.03 (vs US$1.04 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: US$349.8m (up 8.5% from FY 2019). Net income: US$1.40m (down 97% from FY 2019). Profit margin: 0.4% (down from 15% in FY 2019). Post-clinical trial products Pre-registration: 6 Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 10Amphastar Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 15, 2021Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2020 results After-Market on Mar 15, 2021
Is New 90 Day High Low • Feb 25New 90-day low: €14.50The company is down 2.0% from its price of €14.80 on 26 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €66.42 per share.
お知らせ • Jan 28Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic IndexAmphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index
お知らせ • Dec 30Amphastar Announces Approval for Glucagon for Injection Kit, 1mgAmphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin. Amphastar plans to launch this Glucagon for Injection Emergency Kit, which it previously referred to as AMP-001, within two months. The Company currently has four ANDAs filed with the FDA, which are targeting products with a market size of approximately $1.4 billion, three biosimilar products in development targeting products with a market size of approximately $13.0 billion, and nine generic products in development targeting products with a market size of approximately $12.0 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2020. The Company is developing multiple proprietary pipeline products for injectable and intranasal dosage forms, including a new drug application for intranasal naloxone and intranasal epinephrine. Amphastar’s Chinese subsidiary, ANP, currently has 14 Drug Master Files, or DMF, on file with the FDA and is developing several additional DMFs.
Is New 90 Day High Low • Nov 24New 90-day low: €15.00The company is down 12% from its price of €17.00 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €57.82 per share.
Analyst Estimate Surprise Post Earnings • Nov 07Revenue misses expectationsRevenue missed analyst estimates by 8.6%. Over the next year, revenue is forecast to grow 29%, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany.
Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS US$0.083The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$83.4m (up 4.1% from 3Q 2019). Net income: US$3.92m (up 199% from 3Q 2019). Profit margin: 4.7% (up from 1.6% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 30Amphastar Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 06, 2020Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Nov 06, 2020
お知らせ • Oct 07Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate InjectionAmphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration approved the Company’s Abbreviated New Drug Application for Atropine Sulfate injection 0.1mg/mL in the 10 mL Luer-Jet® Prefilled Syringe System. For the past 40 years, the Company has sold and marketed the product under the “grandfather” exception (now termed unapproved) to the FDA’s “Prescription Drug Wrap-Up” program. Net revenues for the Company’s Atropine Sulfate injection for the year ended December 31, 2019 were $12.2 million.
Is New 90 Day High Low • Sep 23New 90-day low: €15.80The company is down 16% from its price of €18.80 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €49.06 per share.
お知らせ • Jul 31Amphastar Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 06, 2020
お知らせ • Jul 04Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic IndexAmphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index
